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After in vitro testing (confirmed in vivo) of three con•
temporary valve designs (St. Jude, Bjork-Shiley and 
Carpentier-Edwards) demonstrated that the St. Jude valve 
possessed the most favorable hydrodynamic perform•
ance ~haracteristics, a limited clinical trial was begun 
in high risk patients who might benefit from a prosthesis 
with improved hemodynamics. Between March 1978 and 
March 1984, 419 St. Jude prostheses (157 aortic, 156 
mitral and 53 double aortic-mitral) were implanted in 
366 patients. Ninety-six percent were in New York Heart 
Association functional class III or IV preoperatively. 
Early (30 day) mortality was 10.4% overall, and was 
lower after aortic (5.7%) or double (7.5%) than after 
isolated mitral valve replacement (16.0%). Forty-four 
prosthetic mitral valve recipients with severe ischemic 
mitral regurgitation experienced a 32 % early mortality 
rate; without this group, mitral valve replacement car•
ried a 10% early mortality rate (p < 0.01). 
Multivariate logistic regression analysis confirmed that 
early death was strongly as,!ociated with three preop•
erative patient characteristics (p < 0.05): ischemic mi•
tral valve disease, depressed left ventricular function 
(ejection fraction < 0.55) and advanced functional class 
(class IV). Late follow-up (7,055 patient-months, mean 
22) was 99.7% complete (1 patient lost). Actuarial sur•
vival at 4 years was 80, 80 and 79% after aortic, mitral 
(nonischemic) and double valve replacement, respec-
Valve excision and replacement often result in a host of 
new problems for patients with valvular heart disease. Be•
cause there is, as yet, no ideal valve substitute, improvement 
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tively; in the subset with ischemic mitral regurgitation, 
actuarial survival was 34% (p < 0.01). Eighty-six per•
cent of survivors were in functional class I or II. 
Valve-related complications occurred in 28 patients 
(4.8% per patient-year). Embolism (14 events, 2.4% per 
patient-year) was more common after double (4.8% per 
patient-year) than after aortic (2.1 % per patient-year) 
or mitral (1.7% per patient-year) valve replacement and 
more frequent in patients receiving aspirin and dipy•
ridamole (7.7 % per patient-year) than in those receiving 
warfarin (2.5% per patient-year). Cinefluoroscopy by 
computer-enllanced techniques allowed excellent visu•
alization and quantitative analysis of normal and ab•
normal St. Jude valve function. 
In conclusion, the St. JmJe bileaflet valve exhibits 
excellent bemodynamic performance in vitro and in vivo, 
and is associated with a low incidence of embolic com•
plications in patients with adequate anticoagulation. The 
increased early and late mortality rate in prosthetic mi•
tral valve recipients reflects the inclusion of high risk 
patients with ischemic mitral regurgitation, reduced left 
ventricular function and advanced functional class. 
Computer-enhanced cinefluoroscopy is an important tool 
for assessment of St. Jude valve function during follow•
up. 
(J Am Coli CardioI1985;6:904-12) 
in hemodynamic function after valve replacement has often 
been achieved only at the expense of an increased risk for 
valve-related complications such as thrombosis, embolism, 
hemolysis, bleeding and infection (1). Even with bioprosth•
etic valves, which have the lowest rate of complications, 
valve durability has been a significant problem (2). 
Evaluation of any new valve prosthesis must be carried 
out with certain criteria in mind. First, the hemodynamic 
performance of the new valve substitute, in vivo and in 
vitro, must be equal to or better than that of previous valve 
designs. Second, the new prosthesis should be durable and 
not subject to sudden structural failure. Third, there should 
be a low incidence of valve-related complications. Finally, 
these characteristics should lead to improvement in the pa-
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tient's symptomatic status and longevity. 
Because no cardiac valve substitute achieves all of these 
goals equally well, the choice of valve substitute should be 
based on the individual needs of the patient. Age, size of 
the patient, etiology of the valvular disease, anatomic le•
sions, size of the valve anulus, coexisting coronary. artery 
disease, status of ventriculat function, thromboembolic risk 
and contraindications to the use of anticoagulant drugs are 
some of the individual patieht characteristics that should be 
considered in the decision-making process for each patient. 
The need for several prosthetic designs is apparent. 
The St. Jude Medical prosthesis is a bileaflet valve. 
Promising preliminary hemodynamic studies (3-5) led us 
to initiate a limited clinical trial in March 1978 involving 
patients we believed might benefit from a prosthesis with 
improved hemodynamics. This report summarizes our ex•
perience with the st. Jude valve during the first 6 years of 
its use at our institution. 
Methods 
Prosthetic design. The St. Jude valve (Fig. 1) is a low 
profile, bileaflet mechanical prosthesis with three flow ori•
fices. The components (anulus and two leaflets) are man•
ufactured as single units from machined graphite carbon 
without weld points or seams. All surfaces are coated with 
pyrolytic carbon, a material with low thrombogenicity in 
vivo (4). Each leaflet has two rounded protrusions which 
engage pivot points in the orifice ring, allowing each leaflet 
to traverse 55 to 60° during opening; leaflet separation in 
the fully opened position is 10°, whereas in the closed po•
sition it is 120 to 130°. Each leaflet is impregnated with 5 
to 10% tungsten, which allows limited radiographic visi•
bility. The sewing ring is tubular Dacron velour. 
Hydrodynamics in vitro. Because impaired hemody•
namic performance is most likely to be observed in smaller 
valve sizes, an aortic flow model seemed most appropriate 
for defining the in vitro hydraulic performance of a new 
Figure 1. The St. Jude valve in the open position from two per•
spectives: line of view parallel to outflow tract (right) and side 
view (left) demonstrating the large effective orifice area available 
for flow and the low profile of the valve, respectively. 
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cardiac valve substitute. Therefore, a flow apparatus was 
constructed and modeled after the human aortic anulus and 
aortic root, and operated under both steady and pulsatile 
flow conditions. The flow apparatus incorporated multiple 
pressure monitoring ports, an electromagnetic flow meter 
and cannulating flow probe, which were interfaced with a 
microcomputer so that pulsatile flow rate and pressure de•
creases could be measured instantaneously, on-line, beat by 
beat (6). Measurements were made at cardiac outputs rang•
ing from 2.5 to 7.5 liters/min to simulate in vivo physiologic 
conditions. From the pulsatile flow and gradient measure•
ments, effective orifice area (EOA), a measure of the hy•
draulic efficiency of the valve, was calculated according to 
the equation: EOA = QrmJ(51.6 [G1;,]), where Qrms = root 
mean square systolic flow rate (mlls), 51.6 = gravitational 
acceleration constant and G = mean systolic pressure gra•
dient (mm Hg). Performance index (PI), a measure of how 
well a valve utilizes the sewing ring (anulus) area, was 
calculated as a ratio: PI = EOA/sewing ring area. Utilizing 
the previous measurements, the hydraulic performance char•
acteristics of two contemporary prosthetic designs (the Bjork•
Shiley convexo-concave and Carpentier-Edwards porcine 
valves) were compared with those of the St. Jude valve. 
Two-dimensional flow velocity profiles of the St. Jude valve 
were measured by means of a laser-Doppler anemometer 
system coupled to a PDP 11/03 minicomputer. 
Clinical study. Between March 1978 and March 1984, 
446 St. Jude medical prostheses were implanted in 387 
patients at Cedars-Sinai Medical Center. Patients were ex•
cluded from the present study if they had a double valve 
replacement in which the second valve was other than a St. 
Jude prosthesis (12 patients), if they had a tricuspid valve 
replacement alone or in combination with another valve 
replacement (7 patients) or if they had a triple valve re•
placement (2 patients), because of the diversity and small 
number of patients that these groups represented. The re•
maining 366 patients who form the basis of this report had 
single aortic, single mitral or aortic and mitral (double) valve 
replacement with 419 St. Jude prostheses. 
All patients underwent preoperative cardiac catheteriza•
tion and coronary angiography. Pathophysiology and etio•
logic classification of the valve disease was based on the 
findings at catheterization, surgery and after pathologic ex•
amination of the excised valve (7,8). 
Surgical technique. Cardiopulmonary bypass was ac•
complished with a bubble oxygenator. Myocardial preser•
vation techniques included moderate systemic hypothermia 
(25°C), topical cooling of the myocardium with electrolyte 
solution (Normosol) at 4°C and intermittent multidose po•
tassium cardioplegia (St. Thomas or modified blood solu•
tion) infused into the aortic root or coronary ostia at 4°C. 
Aortic valve replacement was performed in 157 patients, 
mitral valve replacement in 156 and double aortic and mitral 
valve replacement in 53. Coronary revascularization was 
required in 186 patients (51%), the valve-specific incidence 
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rates being 57% for aortic, 49% for mitral and 36% for 
double valve replacement. In a subset of 31 patients (8%), 
additional procedures included tricuspid anuloplasty, repair 
of ventricular septal defect, ventricular aneurysmectomy, 
mitral valve repair and composite graft replacement of the 
ascending aljrta. 
Postoper~tive care and follow-up. Permanent antico•
agulation with sodium warfarin was instituted within 72 
hours postoperatively. The level of anticoagulation was ad•
justed to maintain the prothrombin time at twice the control 
value. Patients who experienced recurrent anticoagulation•
related complications, or in whom anticoagulant therapy 
was contraindicated by prior medical problems, were placed 
on an antlplatelet regimen of aspirin and dipyridamole. 
Follow-up has been 99.7% complete (one patient lost). 
Hospital survivors (n = 328) have been followed up for a 
total of 7,055 patient months (mean 22). The method of 
follow-up and classification of causes of death have been 
outlined previously (8). 
Valve-related compiications were defined as structural 
failure, valve thrombosis, embolization, major warfarin•
related hemorrhage necessitating hospitalization, hemo•
lysis, infective endocarditis, paravalvular leak and erosion 
into the atrioventricular (A V) groove. Criteria for emboli•
zation were 1) strokes with permanent neurologic sequelae; 
2) transient unexplained episodes of hemiparesis, visual or 
speech impairment, dizziness or loss of memory; or 3) sud•
den occurrence of abdominal dr peripheral pain and ischemia 
(peripheral embolization). 
Remodynamic studies in vivo. The hemodynamic per•
formance of 55 aortic valves (22 St. Jude, 8 Bjork-Shiley, 
15 Carpentier-Edwards and 10 Hancock; sizes 23 and 25) 
was studied within 24 to 48 hours postoperatively. Mea•
surements included left ventricular pressures with use of a 
surgically placed polyvinyl catheter, radial arterial pressure 
with use of a percutaneous catheter and thermodilution car•
diac output performed in duplicate with use of pulmonary 
artery flotation catheter (9). Measurements were repeated 
during isoproterenol infusion (8 ILg/ml) at a rate sufficient 
to increase the heart rate to 120 beats/min (mean 0.04 ILg/kg 
per min). Pressures were recorded with an Electronics for 
Medicine VR-6 recorder, utilizing a light-sensitive paper at 
100 mm/s. Mean gradient was determined by planimetry; 
In the presence of atrial fibrillation, the mean gradient was 
averaged over 10 beats. Mean diastolic flow and effective 
orifice area were calculated from the Gorlin relation, uti•
lizing a constant of 38 for mitral and 44.3 for aortic valves. 
Cineftuoroscopy. Sixteen patients who had had St. Jude 
valve replacement (eight aortic and eight mitral) within the 
previous year, had normal prosthetic auscultatory findings 
and were in New York Heart Association functional class 
I underwent cinefllioroscopy with computer enhancement 
and digital subtraction (10). Cinefluoroscopy was performed 
with a Philips Maximus M-100 C-arm X-ray generator with 
an Eimac 1 million heat unit X-ray tube and a Thompson 
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image intensifier. A tangential view of the St. Jude valve 
was optimal for leaflet visualization. Images were acquired 
at 30 frames/s and were processed with an ADAC DPS-
4100 on-line computer. 
Statistical methods. Values of continuous variables are 
expressed as mean ± standard deviation. Comparisons be•
tween continuous variables for two groups were made with 
the unpaired t test. Comparisons among continuous vari•
ables for three groups were made with one-way analysis of 
variance (ANOV A) followed by Scheffe's multiple com•
parisons if the ANOV A probability value was less than 0.05. 
Discrete variables were compared by means of chi-square 
analysis by Fisher's exact test. Survival curves were con•
structed by the life table method, and all deaths were in•
cluded intRe analysis. Differences between survival curves 
were assessed by the generalized Wilcoxon test. To deter•
mine which variables were predictive of mortality, a mul•
tivariate logistic regression model was derived. First, vari•
ables were univariately screened for their association (p < 
0.20) with death. Those variables selected by the screening 
process were entered into the logistic regression model to 
determine which were most strongly and independently as•
sociated with mortality. All statistical calculations were per•
formed utilizing BMDP statistical software (11). 
Results 
Hydrodynamics In Vitro 
Under pulsatile conditions at varying flow rates, the in 
vitro performance of the St. Jude, Bjork-Shiley convexo•
concave and Carpentier-Edwards valves was compared (Fig. 
2). For each valve size (21, 25 and 27 mm), the gradient 
Figure 2. In vitro gradient measurements at varying pulsatile flow 
rat.eS (6). The St. Jude prosthesis is compared with two other 
contemporary valve designs: the Bjork-Shiley convexo-concave 
valve and the Carpentier-Edwards porcine bioprosthesis (sizes 21, 
25 and 27 mm). 
38 
34 
30 
11. 
f? 
0 26 
Ir2 
lei 18 g~ 
14 
(J) 
~ 
Z « 10 
~ 
6 
100.21 
_._. PORCINE 
-SJORK-!H..EY 
--- ST. Jl.()E 
o 100 200 300 400 0 100 200 300 400 
PULSATILE SYSTOLIC FLOW 
ROOT MEAN SQUARE 
Otw,mllsec 
38 
34 
30 
26 
22 
jl8 
JACC Vol. 6, No.4 
October 1985:904-12 
Table 1. Effective Orifice Area, Performance Index and 
Regurgitant Volume Determined In Vitro fo~ the St. Jude, 
Bjork-Shiley Convexo-Concave and Carpentier-Edwards 
Valves (6) 
Valve 
St. Jude 
Bjork -Shiley 
convexo-concave 
Effective 
Orifice 
Area (cm2) 
Performance 
Index 
Regurgitant 
Volume 
(mllbeat) 
21 25 27 21 25 27 21 25 27 
2.08 3.23 4.09 0.60 0.66 0.71 7.6 9.7 10.6 
1.54 2.37 2.59 0.45 0.48 0.45 5.5 7.3 8.5 
Carpentier-Edwards 1.05 1.52 1.95 0.30 0.31 0.34 0.8 1.2 0.9 
porcine 
was smallest for the St. Jude valve. As a result, the effective 
orifice area and performance index were highest for the St. 
Jude valve (Table 1). The St. Jude valve, therefore, was 
hydraulically more efficient than the Bjork-Shiley convexo•
concave or Carpentier-Edwards valves. 
Regurgitant volume was somewhat greater for the St. 
Jude valve than for the Bjork-Shiley convexo-concave valve 
(Table 1). Both mechanical valves, however, had a larger 
regurgitant volume than did the porcine bioprosthesis. 
Flow visualization of the St. Jude prosthesis by laser•
Doppler velocity measurements demonstrated near-laminar 
central flow with minimal turbulence (Fig. 3). Flow through 
all three orifices (one central and two side) was large enough 
to prevent stagnation downstream from any orifice. Maximal 
turbulent shear stress was 750 dynes/cm2. 
Clinical Study 
Of the 366 patients who entered this study (mean age 63 
years; 59% female), 96% were in functional class III or IV 
preoperatively (Fig. 4). There was moderate to severe left 
ventricular dysfunction in 36%, as evidenced by a left ven-
Figure 3. Flow velocity profiles of size 27 St. Jude prosthesis in 
plane perpendicular (A) and parallel (B) to open leaflets (6). 
/ , 
/ , 
/ 
/ , 0 
/ -8 
A B 
(/) 
>•z w 
~ 
200 
PRE-OPERATIVE 
CZER ET AL. 
ST. JUDE VALVE 
(60%) 
174 
74 
o ALIVE 
I:!l DEAD 
(12%) 
POST -OPERATIVE 
907 
Figure 4. Preoperative and postoperative Ne:-v York H~art As•
sociation functional class in study patients. Patients who dIed dur•
ing follow-up (hatched areas) were concentrated in the more 
advanced functional classes preoperatively. 
tricular ejection fraction of less than 0.55. Concomitant 
coronary artery disease was present in 57% (12% single 
vessel, 12% double vessel, 29% triple vessel and 4% left 
main disease). Forty-four (28%) of 156 mitral valve recip•
ients had severe ischemic mitral regurgitation necessitating 
valve replacement. Thus, the study group represented rel•
atively high risk patients who required valve replacement. 
Mortality rate. The early (30 day) mortality rate was 
10.4% (38 deaths) (Table 2). The mortality rate after aortic 
(5.7%) or double (7.5%) valve replacement was signifi•
cantly lower than that after mitral (16.0%) valve replace•
ment. In the latter group, 44 patients with ischemic mitral 
regurgitation experienced a 32% early mortality rate com•
pared with a 10% mortality rate in the 112 remaining patients 
who underwent mitral valve replacement (p < 0.05). Ex•
cluding the high risk subset of 44 patients with ischemic 
mitral regurgitation, overall early mortality rate was 7.5% 
(24 of 322 patients). 
There were 37 late deaths for an overall 10.1% late 
mortality rate (Table 2). Again, mortality rate was lower 
in the aortic (7.6%) or double (7.5%) valve recipients than 
in the mitral valve cohort (13.5%). Analysis of total mor•
tality by the life table method (Fig. 5) shows that actuarial 
survival at 4 years was 80 ± 5% in the aortic valve cohort 
and 79 ± 8% in the double valve cohort compared with 65 
Table 2. Mortality and Cause of Death 
Valve 
All 
Aortic Mitral Double Positions 
(n = 157) (n = 156) (n = 53)(n = 366) 
Mortality 
Early (%) 9 (5.7) 25 (16.0) 4 (7.5) 38 (10.4) 
Late (%) 12 (7.6) 21 (13.5) 4 (7.5) 37 (10.1) 
Cause of death 
Cardiac valvular (%) 2 (9%) 4 (8%) 0 6 (8) 
Cardiac nonvalvular (%) 9 (43) 32 (70) 6 (75) 47 (63) 
Noncardiac (%) 10 (48) 10 (22) 2 (25) 22 (29) 
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Figure 5. Actuarial survival rates after aortic (A VR), double aor•
tic-mitral (DVR) and mitral (MVR) valve replacement. The 4-year 
survival rates and standard errors were 80 ± 5% (A VR), 79 ± 
8% (DVR) and 65 ± 5% (MVR). The survival rate after mitral 
valve replacement was significantly lower than that after aortic or 
double valve replacement (p < 0.0l). Numbers below the figure 
indicate patients at risk during foHow-up. 
± 5% in the mitral valve cohort (p < 0.05). However, 
excluding patients with ischemic mitral regurgitation (4 year 
survival 34 ± 13%), mitral valve recipients experienced a 
4 year survival of 80 ± 7%. Six patients died from valve•
related causes, two of which were due to prosthetic erosion 
through the A V groove, producing sudden massive hem•
orrhage and tamponade intraoperatively. The other four deaths 
were due to intracerebral hemorrhage in patients receiving 
warfarin anticoagulation therapy, and because we consid•
ered this mode of therapy necessary with this prosthesis, 
these deaths were classified as valve related. Cardiac non•
valvular causes accounted for 47 of the 75 deaths and were 
attributable to heart failure, arrhythmia or sudden death with 
no other explanation. Thirty-two of these deaths occurred 
in the mitral valve cohort (Table 2). Noncardiac deaths (22 
of 75) were due to malignant neoplasia, trauma, pulmonary 
failure, aspiration pneumonia and renal failure. 
A multivariate logistic regression model demonstrated 
that the following preoperative characteristics were inde•
pendently associated with an increased risk of early death 
(p < 0.05, improvement in chi-square): ischemic mitral 
regurgitation, a depressed left ventricular ejection fraction 
«55%) and advanced functional class (class IV). In gen•
eral, survivors experienced an excellent functional result; 
86% were in functional class I or II at latest follow-up (Fig. 
4). 
Valve-related complications. The most common valve•
related complication was embolism (14 events), which oc•
curred at an annualized event rate of 2.4% per patient-year 
of follow-up (Table 3). All of the embolic events were 
neurologic in nature. Thirteen events were transient and 
without sequelae, one resulted in residual hemiparesis and 
none were fatal. The embolic rate varied with valve position, 
Table 3. Valve-Related Complications 
Valve 
Complication Aortic Mitral 
Structural failure 0 0 
Hemolysis 0 0 
Erosion 0 2 
Endocarditis I I 
Anticoagulant-related 3 4 
Thrombosis 3 0 
Embolism 5 4 
All complications 12 II 
Rate per patient-year (%) 
Embolism 2.1 1.7 
All complications 5.1 4.5 
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Double Total 
0 0 
0 0 
0 2 
0 2 
0 7 
0 3 
5 14 
5 28 
4.8 2.9 
4.8 4.8 
being 2.1% after aortic, 1.7% after mitral and 4.8% after 
double valve replacement. In three patients whose antico•
agulation therapy was inadequate, the aortic valve throm•
bosed 0.2% per patient-year); two of the three were re•
operated on and survived and one was treated successfully 
with streptokinase. 
Major warfarin-related morbidity (bleeding episodes re•
quiring hospitalization) occurred at a rate of 1 % per patient•
year (seven events). Among 23 patients not receiving war•
farin, the thromboembolic rate was 7.7% per patient-year, 
which was triple the rate of patients maintained on warfarin 
anticoagulation (2.5% per patient-year). Thus, in our ex•
perience, the risk of thromboembolism associated with in•
adequate anticoagulation far exceeded the risk of bleeding 
associated with the use of warfarin, and we continue to 
recommend warfarin anticoagulation for all patients. Certain 
preoperative patient characteristics placed the patient at higher 
risk for postoperative thromboembolism (Table 4). These 
Table 4. Relation of Selected Preoperative Patient 
Characteristics to Postoperative Thromboembolic Rate 
Patients Rate per 
Preoperative at Risk Postoperative 100 
Variable (%) Events Patient-Years 
Left atrial thrombus 
Present 15 (4) 2 5.7 
Absent 350 (96) 15 2.8 
Prior history of embolus 
Present 30 (8) 3 5.6 
Absent 332 (92) 14 2.7 
Rhythm 
Atrial fibrillation 94 (27) 7 4.3 
Normal sinus 222 (65) 10 2.7 
Left atrial size 
Large or moderate 168 (48) 8 2.5 
Normal or small 183 (52) 9 3.5 
Sex 
Female 215 (59) to 2.9 
Male 151 (41) 7 3.0 
Risk 
Ratio 
2.0 
2.0 
1.6 
0.7 
1.0 
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Figure 6. Freedom from thromboemboli (solid line) and from all 
valve complications (dashed line) in study patients. At 4 years, 
the probability of freedom from thromboemboli was 91 ± 3%, 
and freedom from all valve complications was 87 ± 3%. Numbers 
below the figure indicate patients at risk during follow-up. 
included the presence of a left atrial thrombus (despite sub•
sequent thrombectomy), a history of thromboembolic events 
before surgery and the presence of atrial fibrillation. Left 
atrial size and gender did not affect the thromboembolic 
rate in this analysis. 
No structural valve failures were observed during this 
study (Table 3). Bacterial endocarditis occurred late in two 
patients (0.5%), resulting in paravalvular insufficiency; val•
vular erosion through the A V groove occurred in two other 
Figure 7. In vivo gradient measurements at rest and after isopro•
terenol infusion (9). The St. Jude prosthesis was compared with 
the Bjork-Shiley and Carpentier-Edwards valves (sizes 23 and 25 
mm). In addition, the Hancock porcine valve is shown in the 25 
mm size; its hemodynamics were similar to those of the Carpentier•
Edwards bioprosthesis. 
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patients. No evidence of clinically important hemolysis was 
observed in 50 consecutive patients studied 2.5 years after 
valve replacement (8). Reoperation was necessary because 
of the two valve erosions, two of the valve thromboses and 
two paravalvular leaks from late endocarditis; four of the 
six reoperations were successful. 
Thus, a total of 28 complications occurred during 588 
patient-years of follow-up, for an overall complication rate 
of 4.8% per patient-year. At 4 years, 91 % of patients were 
free of thromboembolic complications and 87% were free 
of all complications (Fig. 6). 
Hemodynamics in vivo. Within 24 to 48 hours post•
operatively, the hemodynamic performance of the St. Jude 
valve was compared with that of the Bjork-Shiley and Car•
pentier-Edwards valves (Fig. 7). In the 25 mm size, the St. 
Jude and Bjork-Shiley valves demonstrated similar hemo•
dynamics, and both had much lower gradients than the Car•
pentier-Edwards bioprosthesis. In the smaller size (23 mm), 
however, the St. Jude valve demonstrated a lower gradient 
than either of the other two valves. These in vivo hemo•
dynamic findings confirmed the hydraulic performance char•
acteristics of the St. Jude valve observed in vitro (Fig. 2, 
Table 1). 
Cinefluoroscopy. Sixteen patients with normally func•
tioning prostheses underwent cinefluoroscopy within the first 
postoperative year. Because of the limited radiographic vis•
ibility of the prosthesis, methods of digital subtraction and 
computer enhancement were utilized, which permitted ex•
cellent visualization of the prosthesis (Fig. 8). The leaflet 
separation and velocity varied over a narrow range (standard 
deviation less than 20% of the mean) in the normal valves 
(Table 5). In contrast, two aortic valves functioning ab•
normally because of prosthetic thrombosis demonstrated 
values for leaflet separation in the open position and max-
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Figure 8. Cinefluoroscopic images of a normally functioning St. 
Jude valve after computer enhancement (10). Line of view parallel 
to outflow tract (A) and oblique off-axis view (B) demonstrate the 
prosthetic ring, orifice and leaflets in the open position. Views in 
plane of the prosthetic ring demonstrate leaflets (closed position) 
in the nontangential (C) and tangential (D) projections. The tan•
gential view enables quantification of leaflet separation and ve•
locity during the cardiac cycle. 
imal velocities that were clearly outside the normal range 
(Table 6). 
Discussion 
The excellent hemodynamic performance of the St. Jude 
valve was confirmed both in vitro and in vivo. In comparison 
with two contemporary valve designs (Bjork-Shiley con•
vexo-concave and Carpentier-Edwards), the St. Jude pros-
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Table 6. Leaflet Separation and Velocity in Two 
Abnormally Functioning Aortic St. Jude Valves Due to 
Prosthetic Thrombosis 
Valve 
Leaflet Separation Maximal Velocity 
Size 
(degrees) (degrees/ms) 
Patient (mm) Opened Closed Opening Closing 
I 21 66 125 1.57 1.68 
2 21 58 125 I.:n 1.38 
thesis demonstrated a lower gradient, larger effective orifice 
area and higher performance index (Fig. 2 and 7, Table I), 
Moreover, the velocity profile demonstrated near-laminar 
flow with low turbulence and sheer stresses (Fig, 3). These 
findings have been corroborated by other investigators, both 
in vitro and in vivo (12-16). 
Clinical factors determining early mortality and sur•
vival. On the basis of these promising hemodynamic char•
acteristics, we initiated a limited clinical trial in March 1978 
and incorporated subsets of patients whom we felt might 
benefit particularly from a prosthesis with improved hemo•
dynamics, including patients with a small aortic or mitral 
anulus, a small ventricle or aortic root, left ventricular dys•
function or those who were children. Many of these patients 
were high operative risks, as evidenced by the advanced 
functional class (class III or IV) in 96%, impairment of left 
ventricular function (ejection fraction <0.55) in 36%, pres•
ence of associated coronary artery disease in 58%, ischemic 
etiology of the valvular disease in 28% of mitral valve 
recipients and advanced age of the general study group 
(mean age 63 years). The mortality data reported in this 
paper reflect the bias in patient selection. The negative im•
pact of ischemic mitral regurgitation, left ventricular dys•
function and advanced functional class was confirmed by 
multiple logistic regression analysis, which identified these 
factors as strongly associated with early death postoperatively. 
Coronary artery disease, and ischemic mitral regurgita•
tion in particular, are known to adversely affect outcome 
after mitral valve replacement (7). Forty-four patients in this 
study who underwent valve replacement for ischemic mitral 
regurgitation experienced a 32% early mortality rate and a 
Table 5. Leaflet Separation and Velocity in Normally Functioning St. Jude Prostheses 
Valve 
Leaflet Separation Maximal Velocity 
Valve Size 
(degrees) (degrees/ms) 
Position (mm) Opened Closed Opening Closing 
Aortic (n = 8) 
Range 19 to 25 10 to 13 120 to 127 2.46 to 2.93 2.24 to 3.60 
Mean±SD II± I 124±2 2.72±0.16 3.12±0.46 
Mitral (n = 8) 
Range 27 to 31 10 to 15 126 to 130 2.30 to 2.95 2.19 to 3.27 
Mean±SD 12±2 130± I 2.71 ±0.25 2.82±0.36 
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34% 4 year survival, similar to our experience with other 
valve substitutes (7). However, excluding this exceptionally 
high risk subset, early mortality rate was 5.7% after aortic, 
10.0% after mitral and 7.5% after double valve replacement. 
Similarly, 4 year survival rates were 80, 80 and 79%, re•
spectively. These results are similar to those reported by 
others (14,15,17,18). Moreover, 86% of survivors remained 
in functional class lor II at latest follow-up (Fig. 4). Because 
the majority of patients are operated on primarily for relief 
of symptoms, this goal of valve replacement therapy has 
been well achieved. 
Valve-related complications. The excellent hemody•
namic performance of the St. Jude valve has translated into 
a low incidence of valve-related complications for a me•
chanical prosthesis. Embolism was the most common com•
plication and occurred at an annualized event rate of 2.4% 
per patient-year (Table 3). Several variables increased the 
risk of postoperative thromboembolism. These included pre•
operative factors (left atrial thrombus, prior history of em•
bolism or atrial fibriHation [Table 4]), operative (double 
valve replacement [Table 3]) and postoperative factors (war•
farin anticoagulation). Of these, the highest risk of post•
operative thromboembolism (7.7% per patient-year) was 
imparted by a lack of warfarin anticoagulation; this was also 
the most easily modifiable factor. All three cases of valve 
thrombosis occurred in the setting of inadequate anticoag•
ulation. Thus, we continue to recommend warfarin anti•
coagulation in all patients. An exception to this policy may 
be in children (19), in whom the risk of thromboembolism 
may be lower, the risk of anticoagulation higher and the 
difficulty in monitoring laboratory variables greater. For 
them, we recommend anti platelet therapy with aspirin and 
dipyridamole, if they continue to have normal sinus rhythm. 
Durability of the St. Jude valve has been excellent, with 
no instances of structural failure occurring during the 6 year 
foHow-up of this study. This may be due, in part, to the 
construction of valve components without seams or weld 
points. This is in contrast to the Bjork-Shiley convexo•
concave valve, which has experienced some problems in 
this regard (I). 
Assessment of valve function noninvasively. Such as•
sessment is important in the continuing follow-up of all 
prosthetic valve recipients. Cinefluoroscopy with on-line 
computer-enhancement techniques has provided excellent 
visualization of leaflets in all patients (Fig. 8) and allowed 
quantification of leaflet function (Table 5). Variability in 
measurement of leaflet separation and velocity was small. 
In two patients with surgically confirmed prosthetic throm•
bosis, preoperative cinefluoroscopy demonstrated that the 
function was strikingly abnormal (Table 6). M-mode and 
two-dimensional echocardiography have been less satisfac•
tory, because of the inability to consistently visualize both 
leaflets of the st. Jude valve and to obtain views in the 
proper orientation, given the variability of positioning when 
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the valve is implanted (10,18,20). Doppler methods may 
improve assessment of prosthetic function by ultrasound 
techniques. 
Conclusions. In our experience, certain patient char•
acteristics warrant special consideration of the St. Jude pros•
thesis if valve replacement is required. These include a small 
aortic root or anulus, a small mitral anulus or left ventricle 
and small body size (as in children), because of the low 
profile and excellent hemodynamics in small valve sizes. 
Left ventricular dysfunction may also be an indication for 
this prosthesis, but the poor results with any valve substitute 
in patients with this finding strongly suggest that surgical 
therapy should be recommended earlier, before dysfunction 
occurs, in patients with valvular heart disease. 
We express our gratitude to Helen Schan'lroth and Kathleen Farrington for 
secretarial support. 
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